Seizure Frequency Reduced With Long-Term Adjunctive Brivaracetam

Analysis supports sustained efficacy of brivaracetam 50 to 200mg/day
Analysis supports sustained efficacy of brivaracetam 50 to 200mg/day

VANCOUVER, BC—Long-term adjunctive brivaracetam treatment reduces seizure frequency and sustains seizure freedom, data from a pooled analysis presented at the 68th Annual AAN Meeting have shown.

Brivaracetam is approved as adjunctive therapy for partial-onset (focal) seizures in adults 16 years of age and older with epilepsy. To evaluate its long-term efficacy in open-label use, Manuel Toledo, MD, PhD, of the Department of Neurology, Hospital Vall d'Hebron, Barcelona, Spain, and colleagues pooled data from 6 Phase 2/3 studies and 3 follow-up studies.

A total of 1,904 patients received brivaracetam 5–200mg/day in fixed or flexible doses and 1 or 2 concomitant antiepileptic drugs, most commonly carbamazepine, lamotrigine, valproate, oxcarbazepine, topiramate, levetiracetam, or phenytoin. Concomitant levetiracetam was limited to 20% of patients in two of the studies and was not permitted in one of the studies.

Mean age at baseline was 36.8 years; 51.0% of the patients were male and 70.3% were white.

At the time of the analysis, 22 patients had received brivaracetam for ≥8 years, 1500 (79%) for ≥6 months, 1188 (62%) for 12 months, 847 (44%) for 24 months, and 553 (29%) for 60 months.  

Results showed that "overall, there was a median reduction in partial-onset seizure frequency of 48.8% from baseline," Dr. Toledo reported. By cohort, this reduction was 49.4% in the 6-month group, 56.5% in the 12-month group, 61.1% in the 24-month group, and 65.2% in the 60-month group.

The overall ≥50% responder rate was 48.9%; by cohort, this was 49.3% in the 6-month group, 56.4% in the 12-month group, 63.2% in the 24-month group, and 66.4% in the 60-month group. The percentage of patients continuously seizure-free for the duration of treatment with brivaracetam was 5.3%, 4.6%, 3.7%, and 3.6% in the 6-, 12-, 24-, and 60-month cohorts, respectively.

Health-related quality of life scores also improved for all patients receiving brivaracetam, as measured by the Quality of Life in Epilepsy Inventory-31P test, "with seizure worry showing the most meaningful improvement," Dr. Toledo concluded.

Dr. Toledo received personal compensation from UCB Pharma, BIAL, and Eisai, and received research support from Eisai.

Loading links....